Updated reviews issued for oseltamivir, zanamivir use in flu

Updated reviews issued for oseltamivir, zanamivir use in flu

(HealthDay)—Oseltamivir and zanamivir reduce the time to symptomatic improvement in influenza by about half a day, but evidence to support claims of reduced admissions to hospital or complications of influenza is lacking, according to two systematic reviews of regulatory information published online April 10 in BMJ.

Tom Jefferson, Ph.D., from the Cochrane Acute Respiratory Infections Group in Rome, and colleagues conducted a systematic review of clinical study reports and regulatory information to describe the potential benefits and harms of . Twenty-three trials were included in a reliability and completeness screen and 20 in a formal analysis. The researchers found that oseltamivir reduced the time to first alleviation of symptoms by 16.8 hours in treatment trials on adults, and had an effect in some children. In prophylaxis trials, oseltamivir reduced symptomatic influenza by 55 percent in participants, but had no significant effect on asymptomatic influenza and no indication of a reduction in transmission. In treatment
trials there was no difference in admissions to hospital in adults (risk difference, 0.15 percent; 95 percent confidence interval, −0.91 to 0.78 percent; P = 0.84)
and sparse data in children and for prophylaxis.

Carl J. Heneghan, M.D., from the University of Oxford in the United Kingdom, and colleagues conducted a of clinical study reports and regulatory information to describe the potential benefits and harms of zanamivir. Twenty-eight trials were assessed for appropriate study design and 26 were included in a formal analysis. The researchers found that in adults, zanamivir correlated with 0.60-day reduction in the time to first alleviation of symptoms of influenza-like illness. Zanamivir prophylaxis correlated with a reduction in symptomatic influenza in individuals (risk difference, 1.98 percent).

"Zanamivir reduces the time to symptomatic improvement in adults (but not in children) with influenza-like illness by just over half a day, although this effect might be attenuated by symptom relief medication," Heneghan and colleagues write. "We found no evidence that zanamivir reduces the risk of complications of , particularly pneumonia, or the risk
of hospital admission or death."

Several authors from both studies disclosed financial ties to pharmaceutical companies, including GlaxoSmithKline, the manufacturer of (Relenza).

More information: Full Text - Jefferson
Full Text - Heneghan
Editorial 1
Editorial 2

add to favorites email to friend print save as pdf

Related Stories

Continuing uncertainties surround anti-influenza drug

Jan 18, 2012

Incomplete availability of data has hampered a thorough assessment of the evidence for using the anti-influenza drug oseltamivir, a Cochrane Review has found. However, after piecing together information from over 16,000 pages ...

New research assesses use of Tamiflu, Relenza to prevent flu

Aug 03, 2009

Two common anti-influenza drugs — Relenza and Tamiflu — appear equally effective at preventing common flu symptoms when given before infection, say researchers from the Stanford University School of Medicine. However, ...

Recommended for you

Recorded Ebola deaths top 7,000

2 hours ago

The worst Ebola outbreak on record has now killed more than 7,000 people, with many of the latest deaths reported in Sierra Leone, the World Health Organization said as United Nations Secretary-General Ban ...

Liberia holds Senate vote amid Ebola fears (Update)

6 hours ago

Health workers manned polling stations across Liberia on Saturday as voters cast their ballots in a twice-delayed Senate election that has been criticized for its potential to spread the deadly Ebola disease.

Evidence-based recs issued for systemic care in psoriasis

Dec 19, 2014

(HealthDay)—For appropriately selected patients with psoriasis, combining biologics with other systemic treatments, including phototherapy, oral medications, or other biologic, may result in greater efficacy ...

Bacteria in caramel apples kills at least four in US

Dec 19, 2014

A listeria outbreak believed to originate from commercially packaged caramel apples has killed at least four people in the United States and sickened 28 people since November, officials said Friday.

Steroid-based treatment may answer needs of pediatric EoE patients

Dec 19, 2014

A new formulation of oral budesonide suspension, a steroid-based treatment, is safe and effective in treating pediatric patients with eosinophilic esophagitis (EoE), according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.